Sergei I. Agoulnik;Bruce A. Littlefield;Michael Chapman Byrne
发明人:
Sergei I. Agoulnik,Michael Chapman Byrne,Bruce A. Littlefield
申请号：
US14001737
公开号：
US09637795B2
申请日:
2012.03.16
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The invention provides methods for predicting the efficacy of eribulin, an analog thereof, or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate), in the treatment of a subject suffering from breast cancer by determining the level of particular biomarkers in a sample derived from the subject.
